Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency. We show 15 historical shares outstanding datapoints in our PSTX shares outstanding history coverage, used to compute PSTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PSTX market cap history over the course of time is important for investors
interested in comparing PSTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PSTX versus a peer is one thing; comparing
PSTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PSTX can fluctuate over the course of history.
With this page we aim to empower investors researching PSTX by allowing them to research the PSTX market cap history. |
Free PSTX Email Alerts:
Video: The Importance of Market Cap
